FTC Affiliate Disclosure: This article may contain affiliate links. If you enroll through a link in this article, a commission may be earned at no additional cost to you. This does not influence editorial content.
If you have seen the recent headlines about MEDVi — the AI-powered telehealth startup that reportedly grew from zero to $401 million in its first year selling GLP-1 weight-loss medications — you probably have one question that matters more than any business story: Is it actually safe?
That question took on new urgency in April 2026. MEDVi simultaneously received a wave of mainstream media attention and faced an FDA warning letter, questions about its advertising practices, and legal challenges involving one of its clinical infrastructure partners. For patients who are currently enrolled — or thinking about enrolling — the safety question needs a careful, balanced answer.
This article approaches MEDVi from a patient safety angle. Not as a business story. Not as a technology story. As a healthcare decision that deserves the same level of scrutiny you would apply to any prescription medication program.
Understanding What MEDVi Actually Provides
Before talking about safety, it helps to understand how MEDVi is structured. MEDVi is not a pharmacy, a clinic, or a medical practice. It works as a telehealth platform that connects patients with prescribing clinicians and compounding pharmacies through a digital interface.
The actual medical care comes through partnerships with OpenLoop Health (a nationwide network of licensed clinicians) and CareValidate (a telehealth infrastructure provider). Licensed clinicians within these networks hold independent prescribing authority. They evaluate whether a patient qualifies for GLP-1 medication and make the final prescribing decision. MEDVi's own website states that “OpenLoop Health clinicians retain the decision to prescribe compounded GLP-1s to patients.”
This three-part structure — platform, medical group, pharmacy — is standard across the telehealth weight-loss industry. Companies like Hims, Ro, and Henry Meds run similar models. The structure is not itself a red flag. But it does mean the quality of your care depends heavily on the clinical standards and oversight practices of the partner medical groups, not just the brand name on the website you signed up through.
MEDVi's pricing for compounded GLP-1 medications starts at $179 for the first month of semaglutide injections, with refills at $299 per month. Compounded tirzepatide injections start at $349 per month. Oral GLP-1 tablets start at $249 per month. The company also offers brand-name medication paths, including Wegovy and Zepbound, through a $99 membership plus the cost of the medication itself. All plans are cash-pay — MEDVi does not bill insurance directly, though HSA and FSA funds may be eligible.
Compounded vs. FDA-Approved GLP-1 Medications: The Most Important Distinction
This is probably the single most important thing to understand when evaluating any telehealth GLP-1 program. It applies to MEDVi and every competitor that offers compounded formulations.
FDA-approved GLP-1 medications — brand names like Wegovy (semaglutide), Ozempic (semaglutide, approved for type 2 diabetes), and Zepbound (tirzepatide) — have gone through extensive clinical trials. These trials involved thousands of participants over extended periods. They resulted in specific FDA labeling for approved uses, dosing guidelines, and known risk profiles.
Compounded GLP-1 medications — which represent the bulk of what telehealth platforms like MEDVi dispense — contain the same active ingredients but are prepared by compounding pharmacies rather than the original drug manufacturers. Compounded medications are not FDA-approved as finished products. The FDA does not individually review them for safety, efficacy, or quality — even when they are produced in FDA-regulated facilities.
MEDVi discloses this distinction on its website. That disclosure is important and consumers should take it seriously. It does not automatically mean compounded medications are dangerous. Compounding has a long history in medicine and fills real clinical needs. But it does mean that the rigorous quality controls, batch testing, and manufacturing consistency required for FDA-approved drugs may not apply in the same way to compounded versions.
The FDA has flagged this distinction as a consumer safety concern across the entire compounded GLP-1 market. As of early 2026, the agency has documented adverse events associated with compounded semaglutide and has issued warning letters to more than 30 telehealth companies — including MEDVi — for marketing practices the FDA says could mislead consumers about the regulatory status of compounded products.
The FDA Warning Letter: What It Means for Patient Safety
The FDA's February 2026 warning letter to MEDVi identified misbranding concerns. Specifically, the agency found website language that falsely implied FDA approval or evaluation of MEDVi's compounded products. The FDA also said that claims on the site suggested MEDVi was the entity compounding the medications it sold, which was not accurate.
From a patient safety standpoint, misbranding warnings matter because they go to whether patients are getting accurate information about what they are taking. If a patient believes a compounded medication went through the same FDA approval process as a brand-name drug, that patient cannot give fully informed consent to the treatment.
That said, there is an important line to draw here. The warning letter addressed marketing and labeling practices, not the medications themselves. The FDA did not state that MEDVi's compounded medications were contaminated, improperly formulated, or clinically dangerous. A marketing compliance issue is serious, but it is a different category of problem than a drug safety issue.
MEDVi maintains active LegitScript certification. The company has the chance to fix the issues the FDA identified. Many telehealth companies that receive warning letters successfully address the concerns and continue operating without further enforcement action.
The OpenLoop Health Data Breach: What Current Patients Should Know
In January 2026, OpenLoop Health — one of MEDVi's clinical infrastructure partners — disclosed a significant cybersecurity incident. A threat actor claimed to have accessed records from roughly 1.6 million patients. The potentially exposed information includes names, contact details, dates of birth, and medical information.
If you are a current or former MEDVi patient whose care was provided through OpenLoop Health, here is what you should do:
Watch for notification. OpenLoop has begun notifying affected individuals through state attorney general offices. Texas alone has confirmed more than 68,000 affected individuals.
Check your accounts. Consider placing fraud alerts or credit freezes if you believe your information may have been compromised.
Know your rights. Data breach notifications typically include information about free credit monitoring services and your right to participate in any class-action proceedings.
The data breach is an OpenLoop problem, not something MEDVi caused. But it affects MEDVi patients because the three-part telehealth model means that when an infrastructure partner has a security failure, patients across every consumer brand on that platform can be affected. This is a real trade-off of the telehealth model that consumers should understand.
The Oral Tirzepatide Question
One of the more serious allegations in ongoing litigation involves compounded oral tirzepatide tablets. A November 2025 class-action complaint against OpenLoop and Triad Rx alleges that oral tirzepatide tablets sold through the network — including through MEDVi — have no scientifically proven mechanism of absorption. The complaint argues these tablets cannot deliver a therapeutic benefit.
The science behind this concern is straightforward. Tirzepatide is a large peptide molecule. Digestive enzymes break down peptides of this size before they can cross the intestinal wall and reach the bloodstream. The only FDA-approved oral GLP-1 product, Rybelsus (oral semaglutide), needed a specialized absorption enhancer called SNAC to achieve approximately 1% bioavailability. Even with SNAC, patients must take Rybelsus on an empty stomach with no more than 4 ounces of water, then wait 30 minutes before eating.
Whether compounded oral tirzepatide tablets achieve meaningful bioavailability without a comparable absorption technology is an open scientific question. No published clinical data answers it definitively. This does not prove the tablets are worthless — some patients may experience effects through other mechanisms. But the question is real enough that patients taking oral tirzepatide from any compounding source should bring it up with their prescribing clinician.
Known Side Effects of GLP-1 Medications
Whether you get your GLP-1 medication through MEDVi, another telehealth provider, or a traditional doctor's office, these drugs carry established side effect profiles that every patient should understand:
Common side effects that many patients experience, especially during the dose titration phase, include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and fatigue. These effects usually get better as the body adjusts to the medication. Gradual dose increases help manage them.
Serious but less common risks include pancreatitis, gallbladder complications, kidney problems, and thyroid tumors (seen in animal studies — the relevance to humans is not fully established). Anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not take GLP-1 medications under any circumstances.
These risks apply equally whether you are taking FDA-approved or compounded GLP-1 formulations containing the same active ingredients. The key safety variable is whether the prescribing process includes thorough medical screening to catch contraindications. That depends on the quality of the clinical evaluation, not on which platform you use to access it.
How MEDVi's Safety Profile Compares to Alternatives
MEDVi is not the only telehealth GLP-1 provider, and comparing safety-relevant differences across platforms can help patients make better decisions:
Hims & Hers offers both compounded and FDA-approved GLP-1 medications. Compounded semaglutide starts around $199 per month. Hims has a larger customer service team and is publicly traded, which means its operations face more public accountability through SEC filings. The company has faced its own legal challenges, including a patent infringement lawsuit from Novo Nordisk.
Ro provides both compounded and branded GLP-1 options. Branded Wegovy starts at $199 for the first two months, then $349 per month. Ro clearly separates its brand-name and compounded product lines, which makes it easier for patients to choose an FDA-approved path if that matters to them.
Henry Meds focuses on compounded GLP-1 medications. Semaglutide starts at $197 to $297 per month. Henry Meds has fewer complaints about billing and refund issues compared to MEDVi, though it has a smaller overall customer base.
From a safety standpoint, the most meaningful difference between providers is whether they offer a clear path to FDA-approved medication. Both Ro and Hims provide that option. MEDVi has recently added brand-name Wegovy and Zepbound paths, though the compounded options remain its primary offering.
What to Ask Before Enrolling in Any Telehealth GLP-1 Program
No matter which platform you are considering, these questions can help protect your safety:
Am I getting a compounded or FDA-approved medication? Understand what that means for quality assurance and regulatory oversight. Know the difference before you start.
Who is actually prescribing my medication? Confirm that a licensed clinician — not an algorithm — is reviewing your medical history and making the prescribing decision.
Which pharmacy is filling my prescription? Verify that the compounding pharmacy is licensed in its state and registered with the FDA. Ask whether it operates as a 503B outsourcing facility, which carries a higher regulatory standard.
What happens if I have side effects? Understand how to reach a medical professional through the platform. Know what the expected response time is and whether you can speak to a real person or only message through a portal.
What are the cancellation and refund terms? Read the billing and auto-renewal policies fully before entering your payment information. MEDVi requires cancellation at least 72 hours before your next billing date. Billing confusion is the most common complaint category across telehealth GLP-1 platforms — not just MEDVi.
Have I talked to my own doctor about this? A telehealth assessment, no matter how thorough, may not capture your complete medical history. It may not account for interactions with other medications you are taking. Your primary care physician knows your health profile in a way that a one-time telehealth evaluation cannot match.
The Bigger Picture: Compounded GLP-1 Regulation Is Changing Fast
Patients evaluating any compounded GLP-1 program in 2026 should understand that the rules governing these products are actively shifting.
The FDA has issued warning letters to more than 30 telehealth companies for misleading marketing around compounded GLP-1 products. Drug shortages that originally justified expanded compounding are beginning to ease for certain formulations as Novo Nordisk and Eli Lilly increase manufacturing capacity. When a specific drug comes off the FDA's shortage list, the legal basis for compounding that drug narrows significantly.
Novo Nordisk has also begun pursuing patent infringement claims against telehealth competitors. The outcome of those cases could reshape the compounded GLP-1 market for every provider — not just the ones named in the lawsuits.
What this means for patients: the medication that is available and legal to compound today may not remain so throughout the course of your treatment. If you are relying on a compounded GLP-1 program, have a conversation with your doctor about what your backup plan would be if the compounded version becomes unavailable.
The Bottom Line for Patients
MEDVi operates within a market that is moving fast and facing real regulatory pressure. The company has verifiable legitimacy markers: active LegitScript certification, licensed providers, hundreds of thousands of served patients, and a majority of positive consumer reviews. Gallagher's story and MEDVi's growth trajectory are real, even if the $1.8 billion 2026 projection remains unconfirmed.
The company also has unresolved regulatory and legal questions: the FDA warning letter, infrastructure partner challenges, the oral tirzepatide bioavailability debate, and advertising practice concerns. None of these have been finally decided. The FDA warning letter is advisory, not a conviction. The lawsuits involve allegations, not proven findings. The company continues to operate and hold its certifications.
The safest approach for any patient is to treat a telehealth GLP-1 program as one input into a healthcare decision — not the entire decision. Talk to a physician who knows your medical history. Verify the regulatory status of any platform before enrolling. Read every disclosure. Understand what you are being prescribed and what it is not. Monitor the regulatory environment as it changes. And if something feels off about the experience once you are enrolled, trust that instinct and get a second opinion.
Frequently Asked Questions
Is MEDVi safe to use for weight loss?
MEDVi connects patients with licensed clinicians who prescribe GLP-1 medications. The medications themselves — semaglutide and tirzepatide — have strong clinical evidence behind their active ingredients when manufactured as FDA-approved products. MEDVi's compounded versions contain the same active ingredients but are not individually reviewed by the FDA as finished products. The platform holds active LegitScript certification and uses licensed providers. Safety depends on the quality of the clinical evaluation, proper screening for contraindications, and ongoing monitoring. Talk with your personal doctor before starting any GLP-1 program.
What are the side effects of MEDVi's GLP-1 medications?
Common side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and fatigue — especially during the first few weeks as dosing increases. Serious but rare risks include pancreatitis, gallbladder issues, and kidney problems. People with a history of medullary thyroid carcinoma or MEN2 syndrome should not take GLP-1 drugs. These side effects apply to all GLP-1 medications, not just those dispensed through MEDVi.
Does MEDVi use real doctors?
Yes. Clinical care through MEDVi is provided by licensed clinicians in the OpenLoop Health and CareValidate networks. These are real, licensed medical professionals with independent prescribing authority. MEDVi's website currently lists specific named physicians affiliated with the platform. You can verify any listed physician's credentials through your state's medical licensing board database. Separately, some of MEDVi's advertising has used actors or AI-generated portrayals — the company discloses this on its site — but the actual medical care is provided by licensed clinicians.
What is the difference between compounded and brand-name GLP-1 medications?
Brand-name GLP-1 medications like Wegovy and Zepbound have gone through full FDA clinical trials and are approved as finished products with established safety and efficacy profiles. Compounded versions contain the same active ingredients but are prepared by compounding pharmacies and are not FDA-approved as finished products. Compounded medications may have different inactive ingredients, concentration levels, and quality assurance standards compared to the branded versions.
Should I be worried about the OpenLoop data breach?
If you are a current or former MEDVi patient whose care was processed through OpenLoop Health, your personal and medical information may have been exposed in the January 2026 breach. Watch for formal notification from OpenLoop. Consider placing a credit freeze or fraud alert. Review your financial accounts for unusual activity. You may also be eligible for free credit monitoring services through the breach notification process.
How much does MEDVi cost compared to other telehealth GLP-1 providers?
MEDVi's compounded semaglutide starts at $179 for the first month and $299 per month for refills. Hims starts around $199 per month. Ro offers branded Wegovy at $199 to $349 per month. Henry Meds starts at $197 to $297 per month. MEDVi offers the lowest entry price for compounded semaglutide, but both Ro and Hims provide clearer paths to FDA-approved branded medications if that is important to you.
Are oral GLP-1 tablets from MEDVi effective?
The effectiveness of compounded oral tirzepatide tablets is currently the subject of a class-action lawsuit alleging these products have no proven absorption pathway. The only FDA-approved oral GLP-1, Rybelsus, requires a specialized absorption enhancer to reach even 1% bioavailability. Whether compounded oral tirzepatide achieves therapeutic levels without similar technology is an unresolved scientific question. If you are taking or considering oral tirzepatide tablets from any source, bring this question directly to your prescribing clinician.
Can I use insurance to pay for MEDVi?
MEDVi is a cash-pay service. The company does not bill insurance directly or help with prior authorizations. However, you may be able to use HSA or FSA funds for payment. Some patients also submit claims independently to their insurance for potential reimbursement on brand-name medication options offered through the platform.
This article is for informational purposes only and does not constitute medical advice. Weight management decisions should be evaluated by a qualified healthcare professional. GLP-1 medications are prescription medications that require clinical evaluation. Compounded medications are not FDA-approved finished products. Always consult a licensed healthcare provider before starting any medication.
PiedmontPrimaryCare.com Editorial Team | Published April 2026